CN108498496B - Application of brilliant blue G in preparation of medicine for treating acute CO poisoning - Google Patents
Application of brilliant blue G in preparation of medicine for treating acute CO poisoning Download PDFInfo
- Publication number
- CN108498496B CN108498496B CN201810665889.3A CN201810665889A CN108498496B CN 108498496 B CN108498496 B CN 108498496B CN 201810665889 A CN201810665889 A CN 201810665889A CN 108498496 B CN108498496 B CN 108498496B
- Authority
- CN
- China
- Prior art keywords
- brilliant blue
- poisoning
- acmp
- group
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 title claims abstract description 59
- 231100000572 poisoning Toxicity 0.000 title claims abstract description 29
- 230000000607 poisoning effect Effects 0.000 title claims abstract description 29
- 230000001154 acute effect Effects 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 19
- WGODGFXCRIJNLS-UHFFFAOYSA-N 2-amino-6-methyl-5-pyridin-4-ylpyridine-3-carbonitrile Chemical compound CC1=NC(N)=C(C#N)C=C1C1=CC=NC=C1 WGODGFXCRIJNLS-UHFFFAOYSA-N 0.000 abstract description 36
- 230000000971 hippocampal effect Effects 0.000 abstract description 20
- 238000002474 experimental method Methods 0.000 abstract description 6
- 206010030113 Oedema Diseases 0.000 abstract description 4
- 239000007928 intraperitoneal injection Substances 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000006386 memory function Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 28
- 208000005374 Poisoning Diseases 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 19
- 239000007789 gas Substances 0.000 description 15
- 102000003777 Interleukin-1 beta Human genes 0.000 description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 description 7
- 229940126585 therapeutic drug Drugs 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 231100000861 limb weakness Toxicity 0.000 description 2
- 208000027905 limb weakness Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010066397 Visceral congestion Diseases 0.000 description 1
- 206010065768 Visceral oedema Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an application of brilliant blue G in preparing a medicine for treating acute CO poisoning, and experiments prove that: the brilliant blue G is adopted to carry out intraperitoneal injection on a rat suffering from acute CO poisoning, and is found to be capable of obviously reducing the rat mortality rate caused by ACMP, relieving the edema condition of hippocampal tissues of the ACMP rat, reducing inflammatory reaction and improving the learning and memory functions.
Description
Technical Field
The invention relates to the field of acute CO poisoning treatment, in particular to application of brilliant blue G in preparation of a medicine for treating acute CO poisoning.
Background
Carbon monoxide poisoning is caused by inhalation through the respiratory tract of products produced when carbonaceous materials are incompletely combusted. The poisoning mechanism is that the affinity of carbon monoxide and hemoglobin is 200-fold higher than that of oxygen and hemoglobin, so that carbon monoxide is easy to combine with hemoglobin to form carboxyhemoglobin, which loses the oxygen carrying capacity and function of hemoglobin, and thus the tissue is suffocated. Has toxic effect on tissue cells of the whole body, and especially has the most serious influence on cerebral cortex. The clinical manifestations are mainly hypoxia, whose severity is proportional to the saturation of HbCO. The mild patients have headache, weakness, dizziness and difficult breathing in labor, and the saturation degree of HbCO reaches 10-20%. The symptoms are aggravated, the lips of the patients are cherry red, nausea, vomiting, blurred consciousness, collapse or coma can occur, and the saturation degree of HbCO reaches 30% -40%. Severe coma with high fever, increased tension of limb muscles and paroxysmal or tonic spasm, with HbCO saturation greater than 50%. Patients often have cerebral edema, pulmonary edema, myocardial damage, arrhythmia and respiratory depression, which can lead to death.
Brilliant blue G (also called BBG) is P2X7Specific antagonists of R, in the study of P2X7R plays an important role in vivo experiments of the role played in disease, and brilliant blue G has become the most widely used antagonist. Research in recent years proves that brilliant blue G has neuroprotective effect on many brain diseases. The intervention of brilliant blue G can relieve the neurological symptoms and pathological results caused by Alzheimer disease, spinal injury and cerebral ischemia. The brain damage mechanism caused by ACMP is unknown, the treatment means is single, the incidence rate of the patient prognosis delayed encephalopathy is high, but the influence of brilliant blue G on ACMP is not researched in a relevant way.
Disclosure of Invention
The invention aims to provide application of brilliant blue G in preparation of a medicine for treating acute CO poisoning so as to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme:
the brilliant blue G is applied to the preparation of medicaments for treating acute CO poisoning.
As a further scheme of the invention: the dosage of the brilliant blue G is 26-38 mg/kg.
Compared with the prior art, the invention has the beneficial effects that: the brilliant blue G is adopted to carry out intraperitoneal injection on a rat suffering from CO poisoning, and is found to be capable of obviously reducing the death rate of the rat caused by ACMP, relieving the edema condition of hippocampal tissues of the rat suffering from ACMP, reducing inflammatory reaction and improving the learning and memory functions, has a protection effect on the hippocampal tissues suffering from acute CO poisoning, is beneficial to improving the prognosis and survival quality of ACMP and provides a new idea for clinical research on new drugs for treating CO poisoning.
Drawings
Fig. 1 is a graph showing the change of HbCO concentration in 6h, n-10, of rats after intraperitoneal injection of CO gas at different doses in the application of brilliant blue G in the preparation of a therapeutic drug for acute CO poisoning.
FIG. 2 is a graph showing the effect of BBG on the proinflammatory factor IL-1 β in hippocampal tissues in the application of brilliant blue G in the preparation of a medicine for treating acute CO poisoning.
FIG. 3 is a graph showing the effect of BBG on the hippocampal tissue pro-inflammatory factor TNF-alpha in the application of Brilliant blue G in the preparation of a drug for treating acute CO poisoning.
FIG. 4 is a graph showing the effect of BBG on the proinflammatory factor IL-6 in hippocampal tissue in the application of brilliant blue G in the preparation of a therapeutic drug for acute CO poisoning.
FIG. 5 is a graph showing the effect of BBG on the reduction of the increase in water content in hippocampal tissue in the use of brilliant blue G in the preparation of a therapeutic agent for acute CO poisoning.
Fig. 6 is a graph of the localized voyage training of brilliant blue G in the application of the preparation of a therapeutic drug for acute CO poisoning.
Fig. 7 is a bar graph of the localization navigation training of brilliant blue G in the preparation of a therapeutic drug for acute CO poisoning.
Fig. 8 is a graph showing the results of a space exploration experiment in the application of brilliant blue G in the preparation of a therapeutic drug for acute CO poisoning.
Fig. 9 is a trace diagram of a space exploration experiment in the application of brilliant blue G in the preparation of a therapeutic drug for acute CO poisoning.
FIG. 10 is a graph showing the neuronal cell damage in the CA1 region of hippocampus 3 days after 200 times carbon monoxide poisoning in the application of brilliant blue G in the preparation of a therapeutic drug for acute CO poisoning.
FIG. 11 shows the tissue P2X of hippocampus of ACMP group 6h after rat contamination in the application of brilliant blue G in the preparation of the drug for treating acute CO poisoning7And (3) a change graph of R.
Detailed Description
The technical solution of the present patent will be described in further detail with reference to the following embodiments.
The results after injection of different doses of CO gas show: the rat mortality rate was 0 when 70ml/kg of CO gas was intraperitoneally injected, 50% when 100ml/kg of CO gas was injected, and 100% when 150ml/kg of CO gas was injected. The death rate of rats after ACMP has concentration dependence on the CO gas dose injected in the abdominal cavity, and the dose with the death rate of 45 percent is selected as the optimal molding dose, namely the dose of CO gas injected in the abdominal cavity is 100 ml/kg. See table 1.
TABLE 1 mortality of animals following intraperitoneal injection of different doses of CO gas
Dosage/ml/kg | Number/only | Death number/body | Mortality rate/%) |
70 | 10 | 0 | 0 |
100 | 10 | 5 | 50 |
150 | 10 | 10 | 100 |
Injecting CO gas with different dosages into the abdominal cavity, and detecting for 0.5 h; 2 h; the 6h HbCO hemoglobin concentration results show: except for the control group, the HbCO protein concentration of the other three groups rises after CO gas is injected for 30min, reaches a peak within 1-2 hours, then gradually decreases, the HbCO concentration of a rat reaches 67.5% at most after 70ml/kg of CO gas is injected for 30min, and decreases to 23.43% after the rat is infected with the virus within 6 h. The highest HbCO concentration of CO gas injected by 100ml/kg reaches 80.7 percent, and the HbCO concentration is reduced to 26.78 percent after 6 hours of contamination. The HbCO concentration of the CO gas injected at 150ml/kg reaches 89.97 percent at most, and remains high after 6 hours of infection, which is shown in figure 1.
After different doses of gas CO are injected, results of the death rate of rats and the concentration of HbCO are integrated, and 100ml/kg is selected as the optimal molding concentration, so that the survival rate of experimental animals can be guaranteed, and the change trend of the HbCO after CO poisoning is closest to the reality.
After the abdominal cavity is injected with CO gas for 10min, some rats have symptoms of dysphoria, limb weakness, tachypnea, unstable walking, lethargy and the like. The symptoms are the most serious at 2h, the death rate is the highest, the rats have limb weakness and difficult walking, the skin of the exposed parts such as limbs, corners of mouths and the like is cherry red, and the dissected dead rats have visceral congestion and edema and pink lungs.
Example 1
An application of brilliant blue G in preparing a medicine for treating acute CO poisoning comprises the following specific steps:
firstly, selecting 80 rats with the age of 8-10 weeks, randomly and averagely dividing the rats into a Control group, an ACMP + brilliant blue G group and a brilliant blue G group, and then injecting CO with different doses into the abdominal cavity of the rat to prepare an ACMP model of the rat, wherein the dose of the injected CO is 100 ml/kg;
injecting brilliant blue G into rats of an ACMP + brilliant blue G group and a brilliant blue G group, wherein the injection dose of the brilliant blue G is 30mg/kg, detecting HbCO concentration in venous blood to judge CO poisoning degree, detecting the expression of P2X7RmRNA of rat hippocampal tissues by adopting an RT-PCR method, detecting the edema degree of the hippocampal tissues by adopting a dry-wet weighing method, detecting the contents of IL-1 β, TNF-alpha and IL-6 proinflammatory factors of the hippocampal tissues by adopting an ELISA method, observing the change of cytomorphology in a CA1 region of the hippocampal by HE dyeing, and evaluating learning and memory capacity by adopting a Morris water maze experiment.
As a result, it was found that: first, the survival rates were 100% for both Control and brilliant blue G groups, while the survival rate for ACMP group was 55% for the significantly lower Control group (P < 0.05); the survival rate of the ACMP + brilliant blue G group is 75 percent, is obviously improved (P is less than 0.05) compared with the ACMP group, and the brilliant blue G can reduce the death rate of rats caused by ACMP.
Secondly, the ELISA method is used for detecting the contents of IL-1 β -6 and TNF-alpha of four groups of rat hippocampal tissue proinflammatory factors, namely IL-1 β -6 and TNF-alpha, compared with a Control group and a brilliant blue G group, the contents of IL-1 β, IL-6 and TNF-alpha of an ACMP group are obviously increased (P <0.05), compared with the ACMP group, the contents of IL-1 β -alpha and IL-6 of an ACMP + brilliant blue G group are obviously reduced (P <0.05), compared with the Control group, the contents of the inflammatory factors IL-1 β -6 and TNF-alpha of the brilliant blue G group are slightly lower, but have no statistical significance, and brilliant blue G pretreatment can effectively inhibit CO from inducing release of the hippocampal tissue proinflammatory factors, as shown in figures 2-4.
Thirdly, the water content of the hippocampus tissues is detected by a dry-wet weighing method. The water content of the hippocampal tissues of the Control group and the brilliant blue G group was 79.22% + -0.82% and 78.97% + -0.71%, respectively, with no significant difference therebetween. The water content of hippocampal tissue in ACMP group is 80.72% + -0.93%, which is significantly higher than that in Control group (P < 0.05). Whereas the water content of hippocampal tissue was 79.56% ± 0.63% in ACMP + brilliant blue G group, which was significantly lower than that in ACMP group (P < 0.05). It was demonstrated that brilliant blue G pretreatment significantly improved ACMP-induced hippocampal edema, as shown in fig. 5.
Fourthly, performing positioning navigation training for 7 days, and displaying the result: escape latency for all rats was 46.25s on day 1, decreased to 14.02s on day 7, and there was no significant difference between the four groups (P >0.05), see fig. 6-a. After the rats in each group are treated by corresponding medicaments on day 8, the escape latency between the brilliant blue G group and the Control group is not statistically different, the escape latency of the ACMP group is remarkably prolonged (P <0.05) compared with that of the Control group, and the escape latency of the ACMP + brilliant blue G group is obviously shorter than that of the ACMP group (P < 0.05); a space exploration experiment is carried out, and the result shows that: the search time in the target quadrant was statistically different in the bright blue G group compared to the Control group, while the search residence time in the target quadrant was significantly shortened (P <0.05) and the trajectory was decreased in the ACMP group compared to the Control group, while the search time in the SE quadrant was significantly prolonged (P <0.05) and the trajectory was increased in the ACMP + bright blue G group compared to the ACMP group. It was demonstrated that brilliant blue G pretreatment improved the decline in learning and memory ability of rats caused by ACMP, as shown in fig. 6-9.
Fifth, HE staining method detects the morphological structure change of four groups of rat hippocampal CA1 zone nerve cells, and the result shows that: the cells of the Control group are densely and regularly arranged, the cell morphology is regular, the cytoplasm is rich, and the boundary between the nucleus and the cytoplasm is clear and visible; the ACMP group hippocampal CA1 area has reduced cell number, disordered cell arrangement, incomplete cell morphology, sparse cytoplasm, fuzzy boundary between nucleus and cytoplasm, deep staining and shrinking of nucleus, and triangular or irregular shape. Compared with the ACMP group, the nucleus fixation phenomenon of the rat hippocampus CA1 area nerve cells in the brilliant blue G + ACMP group is obviously improved, the shape is regular, and the arrangement is regular. The bright blue G group and the Control group have no obvious difference. The results show that brilliant blue G pretreatment can improve neuronal injury in the CA1 region of the hippocampus of rats caused by acute CO poisoning. The appropriate concentration of brilliant blue G alone had no effect on the morphological structure of the CA1 region of rat hippocampal neurons, as shown in fig. 10.
Sixth, RT-PCR results showed P2X in hippocampal tissue of ACMP group7The expression level of R mRNA was significantly higher than that of Control group (P)<0.01), ACMP + BBG group P2X7The expression level of R mRNA was significantly lower than that of ACMP group (P)<0.05), there was no statistical difference between the BBG group and the Control group, see FIG. 11.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. Any reference sign in a claim should not be construed as limiting the claim concerned.
Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and such description is for clarity only, and those skilled in the art should integrate the description, and the embodiments may be combined as appropriate to form other embodiments understood by those skilled in the art.
Claims (3)
1. The brilliant blue G is applied to the preparation of medicaments for treating acute CO poisoning.
2. The use of brilliant blue G in claim 1 for the preparation of a medicament for the treatment of acute CO poisoning, wherein brilliant blue G is administered in an amount of 26-38 mg/kg.
3. Use of brilliant blue G according to claim 2 in the preparation of a medicament for the treatment of acute CO poisoning, in a dose of 30 mg/kg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810665889.3A CN108498496B (en) | 2018-06-26 | 2018-06-26 | Application of brilliant blue G in preparation of medicine for treating acute CO poisoning |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810665889.3A CN108498496B (en) | 2018-06-26 | 2018-06-26 | Application of brilliant blue G in preparation of medicine for treating acute CO poisoning |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108498496A CN108498496A (en) | 2018-09-07 |
CN108498496B true CN108498496B (en) | 2020-04-07 |
Family
ID=63403798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810665889.3A Expired - Fee Related CN108498496B (en) | 2018-06-26 | 2018-06-26 | Application of brilliant blue G in preparation of medicine for treating acute CO poisoning |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108498496B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY148461A (en) * | 2007-04-10 | 2013-04-30 | Lundbeck & Co As H | Heteroaryl amide analogues as p2x7 antagonists |
-
2018
- 2018-06-26 CN CN201810665889.3A patent/CN108498496B/en not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
P2X7 Receptor Signaling Contributes to Sepsis-Associated;Luiz Eduardo Baggio Savio1,etal;《Mol Neurobiol》;20171231;第6459–6470页 * |
P2X7 受体阻断剂亮蓝G对氧化应激所致红细胞氧化损伤的保护机制;程莹等;《新乡医学院学报》;20160630;第33卷(第6期);第462-465页 * |
急性一氧化碳中毒家兔红细胞微观血流变学变化及其意义的探讨;王喜福等;《中国工业医学杂志》;20101031;第23卷(第5期);第323-326页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108498496A (en) | 2018-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kuluz et al. | The effect of nitric oxide synthase inhibition on infarct volume after reversible focal cerebral ischemia in conscious rats. | |
Vaagenes et al. | Asphyxiation versus ventricular fibrillation cardiac arrest in dogs.: Differences in cerebral resuscitation effects—a preliminary study | |
EP1100589B1 (en) | Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity | |
US20210322407A1 (en) | Use of Trimetazidine in Preparation of Drugs for Preventing and Treating Liver Diseases | |
CN104138377A (en) | A pharmaceutical composition treating severe high-altitude diseases | |
CN113413461A (en) | Medicine for resisting senile dementia and its preparing method | |
CN108498496B (en) | Application of brilliant blue G in preparation of medicine for treating acute CO poisoning | |
TW201902474A (en) | Compounds for treating stroke and reducing nerve damage and uses thereof | |
TWI472519B (en) | N-butylidenephthalide-containing pharmaceutical composition for treating liver injury and improving liver function | |
CN108078999B (en) | Pharmaceutical composition for preventing and treating cerebral arterial thrombosis and preparation method and application thereof | |
AR041947A1 (en) | USE OF ACETYL-L-CARNITINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT TO PREVENT AND / OR TREAT PERIPHERAL NEUROPATHIES INDUCED BY THE ADMINISTRATION OF AN ANTI-TARIFF AGENT INDUCTING NEUROPATHY | |
CN111195253A (en) | Novel application of TRPV4 agonist GSK1016790A | |
WO2021227540A1 (en) | Healthcare device for tonifying vitality of human body | |
CN112569220B (en) | Application of tetrahydrocannabinol in preparation of medicine for treating pulmonary hypertension and pharmaceutical composition containing tetrahydrocannabinol | |
NL2025156B1 (en) | Use of prostaglandin e1 in preparation of medicament for treating intracerebral hemorrhage | |
CN105287985B (en) | Application of pharmaceutical composition in preparing medicine for preventing and treating senile dementia | |
CN104524568B (en) | A kind of pharmaceutical composition for treating obesity and its application | |
CN108210879A (en) | A kind of pharmaceutical composition for treating acute Cerebral bleeding and its application | |
Iliodromitis et al. | Intravenous atenolol and esmolol maintain the protective effect of ischemic preconditioning in vivo | |
KR20210097487A (en) | Composition for preventing, improving or treating sleep disorders comprising fucoidan | |
JP6153838B2 (en) | Vascular permeability inhibitor | |
Kaur et al. | Toxicities and toxicodynamic of anesthetics | |
CN108079305A (en) | The medical composition and its use of cannabidiol and tricyclic antidepressant | |
CN112494637A (en) | Application of salmon calcitonin in preparation of medicines for treating depression | |
Khayal et al. | Role of intravenous lipid emulsion on cardiovascular toxicity induced by combined amitriptyline and citalopram overdoses in adult male albino rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200407 |